GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SINTX Technologies Inc (NAS:SINT) » Definitions » Risk Assessment

SINTX Technologies (SINTX Technologies) Risk Assessment


View and export this data going back to 2014. Start your Free Trial

What is SINTX Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of SINTX Technologies is: No Data: Cannot be evaluated.


Competitive Comparison of SINTX Technologies's Risk Assessment

For the Medical Devices subindustry, SINTX Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SINTX Technologies's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SINTX Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where SINTX Technologies's Risk Assessment falls into.



SINTX Technologies  (NAS:SINT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.


SINTX Technologies Risk Assessment Related Terms

Thank you for viewing the detailed overview of SINTX Technologies's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.


SINTX Technologies (SINTX Technologies) Business Description

Traded in Other Exchanges
Address
1885 West 2100 South, Salt Lake City, UT, USA, 84119
SINTX Technologies Inc is a commercial biomaterial company engaged in using its silicon nitride technology platform to develop, manufacture, and sell a range of medical devices. The company derives product revenue primarily from the manufacture and sale of spinal fusion products used in the treatment of spine disorders. It produces silicon nitride for use in commercial products and product candidates in the forms of Solid Silicon Nitride, Porous Silicon Nitride, and Silicon Nitride Powder, among others. It is also engaged in developing wear-and corrosion-resistant implant components for hip and knee arthroplasty.
Executives
David W. Truetzel director C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET, SALT LAKE CITY UT 84119
David Francis O'brien officer: Chief Operating Officer 1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Ty Lombardi officer: VP Finance C/O AMEDICA CORPORATION, 1885 W 2100 SOUTH, SALT LAKE CITY UT 84119
Eric A Stookey director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Gordon Esplin officer: Vice President, Finance C/O AMEDICA CORPORATION, 1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Kevin Ontiveros officer: See Remarks C/O IMARX THERAPEUTICS INC, 1635 EAST 18TH STREET, TUCSON AZ 85719
Arthur Karl Kipke 10 percent owner C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
Jay M Moyes director, officer: Chief Fnancial Officer
Vytas Rupinskas officer: SVP, Marketing C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Eric K. Olson director, officer: President and CEO C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
James P. Abraham officer: SVP, Global Sales C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Christopher Whitfield officer: Chief Commercial Officer C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Max Link director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Kevin L Davis officer: Chief Operating Officer 9149 SOUTH MONROE PLAZA WAY, SUITE B, SANDY UT 84070
Jeffrey S. White director C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119